Yes, in roughly 5–10% of cases. ALS, also called Lou Gehrig disease, is a progressive neurodegenerative disorder that destroys the motor neurons controlling voluntary movement, and the hereditary form runs in families through specific gene mutations while most cases occur without an obvious inherited cause.
This breakdown separates familial ALS from sporadic ALS, names the genes that drive inherited cases, shows how the disease passes between generations, and explains what genetic testing can and cannot tell you.
The Two Faces of ALS and Why the Distinction Matters
Neurologists divide ALS into two broad categories based on family history, and the split shapes nearly every clinical conversation that follows a diagnosis. Familial ALS (fALS) appears in multiple members of the same biological family, while sporadic ALS (sALS) shows up in someone with no known affected relatives.
Sporadic cases cover roughly 90–95% of diagnoses worldwide. Even that clean split is starting to blur as genetic research reveals that some people labeled as sporadic actually carry ALS-linked mutations, often because family history was never thoroughly documented.
A relative who died young from another cause, a mutation that arose de novo in the patient, or reduced penetrance across a small family can each mask a hereditary pattern. Reduced penetrance means a person carries a mutation but never develops symptoms, which is why silence in a family tree does not rule out inherited risk.
Why Onset Age Differs
Patients carrying a hereditary ALS mutation often notice symptoms years before the typical sporadic onset window of 60–65, sometimes appearing before age 50. A 45-year-old diagnosed with ALS and a parent who died from a similar neurological decline carries a very different clinical profile than a 68-year-old with no family history.
That age gap influences prognosis discussions, eligibility for clinical trials, and the urgency of genetic counseling for adult children still in their reproductive years. Motor neurons in familial cases often face a longer cumulative exposure to the underlying genetic damage, which can accelerate decline once symptoms begin.
Why the Distinction Matters Practically
Knowing whether ALS runs in a family changes conversations with neurologists, genetic counselors, and reproductive specialists. It affects whether other relatives should consider predictive genetic testing, whether children of an affected parent face quantifiable risk, and whether the patient may qualify for gene-specific clinical trials.
A parent with familial ALS may carry guilt about potential transmission, while someone with sporadic ALS may struggle with the apparent randomness of the disease. Both reactions are valid, and recognizing them helps clinicians tailor counseling to the specific emotional reality each family faces.
The Genetics Behind Hereditary ALS
More than 20 genes have been associated with ALS, and four of them account for the majority of inherited cases. Understanding which genes matter, and what each one does, clarifies why hereditary ALS is not a single disease but a collection of related genetic conditions that share a final common pathway of motor neuron death.
The Four Major ALS Genes
C9orf72, SOD1, TARDBP, and FUS account for the majority of identified familial ALS cases worldwide. Each one disrupts motor neuron function through a slightly different mechanism, and each carries its own inheritance pattern, average age of onset, and rate of progression.
| Gene | Share of Familial ALS | Key Characteristic |
|---|---|---|
| C9orf72 | ~40% (European ancestry) | Most common cause; linked to frontotemporal dementia |
| SOD1 | ~20% worldwide | First ALS gene identified (1993); over 200 known mutations |
| TARDBP | ~5% | Encodes TDP-43 protein; also seen in sporadic cases |
| FUS | ~5% | Often associated with younger onset |
| Other genes (TBK1, OPTN, VCP) | Remaining cases | Rarer; each explains a small slice of inherited ALS |
C9orf72 alone explains around 40% of familial ALS in people of European ancestry and roughly 7% of apparently sporadic cases. SOD1 was the first ALS gene identified in 1993, and more than 200 different SOD1 mutations have since been cataloged.
Some SOD1 mutations progress over a few years, while others stretch out over a decade or more, making this gene a striking example of how mutation-specific effects matter as much as the gene itself. Gene-specific trials increasingly use that variability to match patients with targeted therapies.
What These Genes Actually Do
Each ALS-linked gene disrupts motor neurons in its own way. SOD1 mutations cause a toxic gain of function, where the altered enzyme damages cells from the inside. C9orf72 expansions produce abnormal RNA that interferes with protein production.
TARDBP and FUS both affect how cells handle RNA, which is essential for keeping motor neurons alive. The result is the same at the clinical level, progressive weakness and paralysis, but the upstream cause differs enough that gene-specific therapies can target each pathway directly.
How Inherited ALS Passes Through Families
Most familial ALS follows an autosomal dominant inheritance pattern, which means a single copy of the mutated gene from one parent is enough to significantly raise risk. Every child of an affected parent faces a 50% chance of inheriting that copy, and that probability holds for each pregnancy independently.
The math is straightforward on paper and emotionally heavy in practice. A concept called penetrance determines whether carrying the mutation actually leads to the disease, and with many ALS genes penetrance is incomplete.
Some people carry a C9orf72 or SOD1 mutation their entire lives and never develop symptoms. By age 60, roughly 80% of C9orf72 carriers show signs; by age 80, the figure climbs higher but never reaches 100%, leaving a meaningful slice of carriers unaffected.
Does ALS Skip Generations?
Families often ask whether ALS skips a generation, especially when one branch of the family tree looks untouched. The short answer is no: ALS-linked mutations do not reliably disappear and reappear.
Silence in a particular branch usually reflects incomplete penetrance, a small family size where no one else lived long enough for symptoms to surface, or earlier misdiagnosis when an affected relative died of something else before ALS could fully manifest.
Some apparently sporadic cases also trace back to de novo mutations, brand-new genetic changes that arose in the patient and were not inherited from either parent. These cases can create the illusion of a first-time family occurrence, even though the mutation itself has a clear genetic origin.
A Concrete Example
Consider a 52-year-old man diagnosed with ALS whose father died of what was called “muscle wasting” at age 58, before genetic testing existed. The son carries a SOD1 mutation, and the father’s symptoms were almost certainly ALS too.
The son’s three children each face a 50% chance of carrying that same SOD1 change, though whether any of them will actually develop the disease depends on penetrance, which for SOD1 is high but not absolute.
Comparing Hereditary and Sporadic ALS Side by Side
Side-by-side charts show clear contrasts between familial and sporadic ALS in age at onset, progression speed, cognitive involvement, and treatment response. Individual cases vary widely, but the patterns help clinicians and families plan ahead.
| Feature | Hereditary (Familial) ALS | Sporadic ALS |
|---|---|---|
| Share of cases | 5–10% | 90–95% |
| Average onset age | Often before 60 | Usually 60–65 |
| Cognitive and behavioral changes | More common, especially with C9orf72 | Less frequent, but can occur |
| Progression speed | Varies by gene and mutation | Variable; tends toward steady decline |
| Family testing relevance | High | Limited unless rare family pattern emerges |
| Gene-specific trial eligibility | Often applicable | Depends on whether a mutation is found |
Hereditary ALS usually appears 5–10 years earlier than sporadic forms, and certain genetic subtypes carry additional features. C9orf72 carriers, for example, show cognitive and behavioral changes resembling frontotemporal dementia more often than people with sporadic disease.
Progression speed varies dramatically by gene: some SOD1 mutations progress over a few short years, while others unfold over a decade or more. Treatment response and clinical trial eligibility also diverge, since several gene-specific trials target SOD1 and C9orf72 directly.
A confirmed genetic diagnosis can open doors that remain closed to patients without an identified mutation, regardless of whether the family history suggests hereditary disease.
Genetic Testing, Counseling, and What to Consider
Genetic testing for ALS is clinically available, but deciding whether to pursue it involves weighing the value of foreknowledge against psychological, insurance, and family implications. A positive result does not guarantee the disease will ever develop, and a negative result does not eliminate risk entirely, because not all ALS genes have been identified.
When Testing Is Recommended
- Strong family history: Testing is recommended when ALS or frontotemporal dementia appears in multiple relatives across generations.
- Early-onset diagnosis: Patients diagnosed well before age 60 are usually offered testing, since younger onset raises the likelihood of an inherited mutation.
- Known family mutation: When a relative carries a confirmed ALS-linked mutation, testing clarifies whether other family members share it.
- Family planning considerations: Unaffected adults in affected families may consider testing to inform reproductive decisions, though this choice remains deeply personal.
- Clinical trial access: Testing can confirm eligibility for gene-specific trials targeting SOD1, C9orf72, FUS, or other mutations.
What a Genetic Counselor Brings to the Process
A genetic counselor trained in neurodegenerative disease helps interpret test results, explain penetrance in plain language, and guide family planning decisions. The counselor also addresses the emotional weight of results, especially when an unaffected person learns they carry a mutation linked to a fatal disease.
Pre-test counseling typically covers what results could mean, what they cannot tell you, and what support resources exist for either outcome. Post-test sessions help families translate a positive or negative finding into concrete next steps rather than leaving them to absorb the news alone.
Know the limits before you test. A negative genetic panel today does not rule out ALS in the future, because science has not yet identified every gene involved.
Before pursuing testing, ask whether the results will change medical management, whether insurance coverage or life insurance underwriting could be affected, and whether knowing is preferable to not knowing for your specific situation. These are decisions that deserve careful thought, not urgency.
Limits of Current Knowledge and the Research Ahead
ALS genetics is moving faster than at any point in the disease’s history, and what looks like a clean answer today may shift within a few years. Researchers now suspect polygenic risk, meaning the combined effect of many small genetic variations, contributes to some cases currently labeled sporadic.
Large-scale genome-wide studies are starting to map these subtle contributors, which could eventually reshape how ALS risk is calculated. That direction is consistent with reviews in major neurology journals, which increasingly frame ALS as a spectrum rather than a single-condition disease.
Gene-Specific Therapies in Trials
Gene therapy trials targeting SOD1 and C9orf72 are already reshaping what a hereditary ALS diagnosis means in practical terms. Tofersen, an antisense oligonucleotide approved for SOD1-ALS in several countries, can slow progression in patients with specific SOD1 mutations.
Similar approaches are in late-stage trials for C9orf72. A hereditary ALS diagnosis that once carried only bad news now sometimes unlocks access to targeted treatment, and that shift is one of the most meaningful changes in ALS care over the past decade.
Ethical Questions Around Predictive Testing
Asking a healthy person to learn they carry an ALS gene before any symptoms appear forces medicine to confront hard questions it has not fully answered. Professional guidelines recommend that predictive testing only proceed after extensive pre-test discussion and, for many genes, with formal genetic counseling support.
Stay informed through reputable registries and advocacy organizations. Groups like the ALS Association and clinical research networks such as those coordinated through the National Institute of Neurological Disorders and Stroke track emerging therapies and trial enrollment opportunities that directly affect families with hereditary ALS.
Your Next Steps
If a relative has been diagnosed with ALS, start by mapping the family tree back at least two generations and noting any history of motor neuron disease, frontotemporal dementia, or unexplained neurological decline. That record becomes the foundation for a productive conversation with a neurologist or genetic counselor.
Bring specific questions to that meeting: whether testing would change clinical management, what penetrance means for your family, and which trials might be relevant. Genetic counselors and neuromuscular specialists can translate the numbers above into a plan tailored to your situation rather than a general recommendation pulled from a textbook.
FAQ
What percentage of ALS cases are hereditary?
Familial ALS accounts for roughly 5–10% of cases, while sporadic ALS makes up the remaining 90–95%. Improved genetic testing continues to shift some apparently sporadic cases into the hereditary category.
How is ALS inherited from parents?
Most familial ALS follows an autosomal dominant pattern, giving each child of an affected parent a 50% chance of inheriting the mutation. Incomplete penetrance means not every carrier develops the disease.
Which genes cause familial ALS?
C9orf72, SOD1, TARDBP, and FUS together explain most inherited cases. C9orf72 alone accounts for roughly 40% of familial ALS in people of European ancestry, while SOD1 explains about 20% worldwide.
Should I get genetic testing if ALS runs in my family?
Testing is generally recommended for affected individuals and considered for unaffected relatives after genetic counseling. The decision involves weighing the emotional weight of foreknowledge, insurance implications, and whether results will change medical management.
Can you develop ALS without a family history?
Yes. The majority of ALS cases are sporadic, occurring in people with no known affected relatives. Some sporadic cases do carry ALS-linked mutations, often because family history was incomplete or the mutation arose de novo.
What is the difference between familial and sporadic ALS?
Familial ALS appears in multiple family members and usually traces to a known genetic mutation. Sporadic ALS has no clear inheritance pattern, tends to appear later in life, and accounts for roughly 90–95% of cases.
